Pharming Group Presents New Leniolisib Pediatric and CVID Data at CIS 2026 Annual Meeting

summarizeSummary

Pharming Group announced presentations at the CIS 2026 Annual Meeting, sharing new pediatric data for leniolisib in APDS and clinical experience in CVID and related disorders, supporting ongoing trials.

check_boxKey Events

• New Leniolisib Clinical Data Presented

  Pharming Group presented interim safety and efficacy outcomes from a long-term extension study of leniolisib in pediatric APDS patients (4-11 years) and clinical experience data for leniolisib in CVID and CVID-like disorders at the CIS 2026 Annual Meeting.

• Supports Ongoing Phase II Trials

  The clinical observations from expanded access use support two ongoing Phase II clinical trials evaluating leniolisib in CVID and other primary immunodeficiencies with immune dysregulation, with results expected in H2 2026.

• Expands Understanding of APDS and PIDs

  The presentations advance the understanding of Activated PI3Kδ Syndrome (APDS) and other primary immunodeficiencies characterized by immune dysregulation, potentially broadening leniolisib's therapeutic scope.

auto_awesomeAnalysis

Pharming Group's presentations at the Clinical Immunology Society (CIS) Annual Meeting provide new clinical insights into leniolisib, an already approved drug for APDS. The interim pediatric data for APDS and expanded access use in CVID and CVID-like disorders suggest potential for label expansion and broader application. These findings support ongoing Phase II trials, with results anticipated in the second half of 2026, which could further enhance the drug's market potential.